Biotech breakthrough: Mersana Therapeutics stock soars 23% after blowing past Q3 expectations
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer treatment, saw its shares leap by 23% following a robust ... Read More
Merck and Mersana Therapeutics to co-develop new immunostimulatory ADCs
Merck has announced a collaboration with US-based Mersana Therapeutics to discover new antibody-drug conjugates (ADCs) by leveraging the latter’s proprietary Immunosynthen STING-agonist ADC platform. The ... Read More